DETECT: Target Volume for Rectal Endoluminal Radiation Boosting
ConditionRectal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMaastricht Radiation Oncology
About this trial
The aim of the study is to provide prospective data regarding microscopic tumor spread in all directions from the macroscopic tumor in pathology specimens, as seen by eye, and on imaging to define the target volume for endoluminal radiation boosting in rectal cancer patients.
Eligibility criteria
Qualifiers
≥18 years of age and capable of giving informed consent.
ycT1-3N0(*) residual(**) histology confirmed rectal adenocarcinoma after neoadjuvant radiotherapy or long-course chemoradiotherapy for which patients will undergo TME surgery.
Minimal interval between end of neoadjuvant chemoradiotherapy or radiotherapy: 6 weeks.
Disqualifiers
Patient has received brachytherapy as part of neoadjuvant treatment.
<18 years of age or incapable of giving informed consent.
Patient has not been treated with neoadjuvant radiotherapy or long-course chemoradiotherapy.
Patient will not undergo TME surgery for a ycT1-3N0 residual histology confirmed rectal adenocarcinoma.
Trial design
Treatments tested in this trial
- Ultrasound
- Rectoscopy
- Scan, e.g. CT (resection specimen)
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Maastricht Radiation Oncology
Lead sponsor
Maastricht University Medical Center
Collaborator
Catharina Ziekenhuis Eindhoven
Collaborator
Source ClinicalTrials.gov